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Abstract: Pulmonary toxicity is a rare but severe adverse effect of Rituximab, associated with significant morbidity and 
mortality.  Despite increased reporting, few case reports associated with alveolar hemorrhage due to Rituximab have 
been published. The authors present the case of a 61 year old Caucasian male with a diagnosis of small lymphocytic 
lymphoma who recently completed chemotherapy with Rituximab and Bendamustine. The patient presented to the 
emergency room with a one week history of nonproductive cough associated with shortness of breath and low grade 
fevers. Differential diagnosis at the time of presentation included health care associated pneumonia, Rituximab-induced 
pulmonary toxicity, and Pneumocystis jiroveci infection given his history of lymphoma and treatment with Rituximab. The 
patient was initiated on intravenous (IV) broad-spectrum antibiotics, oral atovaquone, and IV methylprednisolone. A CT 
scan showed bilateral diffuse pulmonary opacities and a video-assisted thorascopic surgery guided lung biopsy revealed 
early diffuse alveolar hemorrhage with no evidence for infection. However, the remaining work-up consisting of blood 
cultures, blood tests, and bronchopulmonary lavage did not produce any suggestive findings. Despite initiating the above 
aggressive therapies, the patient continued to rapidly deteriorate. An autopsy revealed diffuse alveolar hemorrhage of 
the lungs, thought to be secondary to Rituximab toxicity. The authors recommend emphasizing the importance of early 
identification of worsening pulmonary symptoms in patients receiving Rituximab, with diagnostic consideration given to 
Rituximab-related toxicity. 
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INTRODUCTION 
Rituximab is a chimeric monoclonal antibody 
frequently utilized in the treatment of hematologic 
malignancies. Pulmonary toxicity is a rare but severe 
adverse effect of the medication, associated with 
significant morbidity and mortality. Rituximab-induced 
interstitial lung disease is becoming increasingly 
reported, with recent estimated incidences ranging 
from 3.7-10%.[1] Further, Hadjinicolaou et al reported a 
mortality rate of 18% (18/99 cases) due to rituximab-
induced pulmonary toxicity in a systematic review.[1] 
Despite increased reporting, few case reports 
associated with alveolar hemorrhage due to Rituximab 
have been published, adding to the uniqueness of this 
report.[2, 3] 
CASE REPORT 
The authors present the case of a 61 year old 
Caucasian male with a diagnosis of small lymphocytic 
lymphoma who recently completed his sixth cycle of 
chemotherapy with Rituximab and Bendamustine. Six 
weeks after completion of the last cycle of the 
chemotherapy, the patient presented to the emergency 
room with a one week history of nonproductive cough 
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associated with shortness of breath and low grade 
fevers. On presentation, he had a temperature of 36.7 
°C, blood pressure of 133/50 mmHg, heart rate of 60 
beats per minute and a respiratory rate of 30 breaths 
per minute with oxygen saturation of 92% on room air. 
Chest examination was significant for diffuse bilateral 
expiratory wheezing and scattered rhonchi. Laboratory 
findings revealed a white count of 8500 cells/L with an 
absolute lymphocyte count of 420. Chest x-ray showed 
bibasilar lung infiltrates and a chest computed 
tomography (CT) revealed bilateral nodular ground 
glass opacities in the upper lobes. Arterial blood gas 
(ABG) was unremarkable. The differential diagnosis at 
the time included health care associated pneumonia 
(HCAP), Rituximab-induced pulmonary toxicity, and 
Pneumocystis jiroveci infection (PCP) given his history 
of lymphoma, treatment with Rituximab, and low 
absolute lymphocyte count.  
The patient was initially started on empiric broad 
spectrum antibiotic coverage with intravenous 
vancomycin, ceftazidime, and levofloxacin for HCAP 
along with oral atovaquone 750 mg (history of allergies 
to sulfa drugs) twice daily and intravenous 
methylprednisolone 60 mg every eight hours to cover 
for pneumocystis infection. A bronchoscopy with 
bronchopulmonary lavage (BAL) was done on day two 
of hospitalization that was negative for pneumocystis, 
fungi,  virus, mycobacterial strains, and malignant cells.  
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Figure 1: Chest CT Showing Bilateral Diffuse Ground Glass 
Infiltrate. 
Blood cultures and tests for HIV, CMV, aspergillus, 
cryptococcal antigen, and urinary antigens for 
histoplasma were reported to be negative. The patient 
deteriorated clinically over the next few days with 
increased oxygen requirements that prompted a repeat 
chest CT which showed bilateral diffuse pulmonary 
opacities (mosaic ground glass pattern) interspersed 
with areas of air cysts, suspicious for Pneumocystis 
jiroveci pneumonia. A repeat BAL was performed that 
was again negative for PCP. A video-assisted 
thorascopic surgery (VATS) guided lung biopsy was 
done that revealed early diffuse alveolar hemorrhage 
with no evidence for infection. Work-up for vasculitis, 
including ANA, ANCA, and anti-DNA antibodies, was 
negative with normal complement levels. The dosage 
of intravenous methylprednisolone was increased to 90 
mg every eight hours with marked clinical 
improvement. However, as steroids were tapered down 
over the next few days, he became very tachypneic 
with a significant drop in his oxygen saturation. An ABG 
done at the time showed a pH of 7.60, pCO2 of 35, 
paO2 of 49, and HCO3 of 34.4 on eight liters of 
oxygen. He was then transferred to the intensive care 
unit where he was intubated. A repeat chest CT 
excluded pulmonary emboli and showed further 
progression of his bilateral lung infiltrates (Figure 1). 
Unfortunately, his clinical status rapidly deteriorated 
and the patient passed away. An autopsy revealed 
 
 
Figure 2: H & E Pictures of the Lung from Autopsy Showing Diffuse Alveolar Hemorrhage. 
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diffuse alveolar hemorrhage of the lungs (Figure 2), felt 
to be secondary to Rituximab toxicity. 
CONCLUSION 
Rituximab-induced pulmonary toxicities are usually 
severe and potentially fatal. The temporal timeline of 
this case is consistent with other reports of interstitial 
pneumonitis and associated alveolar hemorrhage [1-5]. 
Management of pneumonitis in this patient was 
consistent with that described in the current literature 
[1, 5, 6] and despite aggressive measures, the patient 
succumbed to Rituximab-related complications. The 
authors recommend emphasizing the importance of 
early identification of worsening pulmonary symptoms 
in patients receiving Rituximab, with diagnostic 
consideration given to Rituximab-related toxicity. 
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